Can Palvella Therapeutics cover its short-term obligations?

Its current ratio is 28.88 — current assets exceed current liabilities.

Where does Palvella Therapeutics's balance sheet data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Palvella Therapeutics PVLA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$206.39M+173%	$57.98M-30.6%	$63.57M+228%	$70.43M+257%	$75.63M+296%
Prepaid expenses and other current assets	$1.38M-24.9%	$1.01M-56.2%	$1.15M+312%	$1.34M+106%	$1.84M-38.3%
Total current assets	$263.23M—	$58.99M—	$66.94M—	——	——
Operating lease right-of-use assets	——	——	——	——	——
Long-term investments	——	——	——	——	——
Total assets	$263.76M+232%	$59.56M-32.5%	$66.94M+226%	$73.75M+194%	$79.44M+169%
Accounts payable	$5.44M+22.6%	$4.6M+0.2%	$3.48M+335%	$4.56M+370%	$4.44M+193%
Operating lease liabilities, current	——	——	——	——	——
Total current liabilities	$9.12M+1.5%	$11.34M-5.8%	$10.31M+142%	$9.62M+51.5%	$8.98M+19.2%
Operating lease liabilities, non-current	——	——	——	——	——
Total liabilities	$31.45M—	$31.58M—	$28.26M—	——	——
Preferred stock	——	$0—	$0—	$0—	$0—
Common stock	$14K+27.3%	$12K+9.1%	$11K+1,000%	$11K+1,000%	$11K+1,000%
Additional paid-in capital	$383.42M+143%	$163.34M+4.5%	$161.3M-53.0%	$159.27M-53.5%	$157.49M-54.0%
Retained earnings	-$151.22M-48.4%	-$135.45M-44.5%	-$122.74M+62.4%	-$111.39M+65.6%	-$101.92M+68.1%
Accumulated other comprehensive income (loss)	$95K+3,267%	$83K+2,667%	$104K+133%	-$111K+74.5%	-$3K+99.1%
Total stockholders' equity	$232.31M+318%	$27.98M-55.3%	$38.68M+144%	$47.78M+159%	$55.58M+172%
Total liabilities and stockholders' equity	$263.76M+232%	$59.56M-32.5%	$66.94M+226%	$73.75M+194%	$79.44M+169%
Net Investment in Lease	——	——	——	——	——
Operating lease right-of-use assets	——	——	——	——	——
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	——	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	——	——	——	——	——
Derivative Liability, Current	$0—	$2.2M—	$2.22M—	——	——
Derivative Liabilities - Fair Value	$0—	$2.2M—	$2.22M—	——	——
Derivative Liabilities (Non-Current)	$2.16M—	$2.04M—	$1.92M—	——	——
Total debt	——	——	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$14K+27.3%	$12K+9.1%	$11K+1,000%	$11K+1,000%	$11K+1,000%
Accrued Liabilities And Other Liabilities Current	$3.46M—	$4.35M—	$4.62M—	——	——
Derivative Liability, Noncurrent	$2.16M—	$2.04M—	$1.92M—	——	——
Royalty Agreement Liability	$19.8M—	$17.76M—	$16.02M—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Palvella Therapeutics cover its short-term obligations?: Its current ratio is 28.88 — current assets exceed current liabilities.
Where does Palvella Therapeutics's balance sheet data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.